Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact.

AIMS: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections among older adults, leading to hospitalizations, higher healthcare costs, and mortality. In Sweden, the bivalent RSV prefusion F (RSVpreF) vaccine was appr…

Preview only. Read the full abstract at the source